Referenties
Ozempic® Semaglutide
Op deze pagina vind je een uitgebreide lijst met wetenschappelijke referenties die gebruikt zijn voor de artikelen in onze FAQ-sectie over Ozempic® (semaglutide). Deze bronnen zijn zorgvuldig geselecteerd via gerenommeerde databases zoals PubMed en andere wetenschappelijke platforms. De referenties zijn afkomstig uit vooraanstaande medische tijdschriften, wetenschappelijke publicaties en officiële gebruiksinstructies. Ze bieden een diepgaand inzicht in de effectiviteit, veiligheid en toepassing van Ozempic® bij gewichtsmanagement.
Referenties
1. Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial (2024). Current Problems in Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S0146280623004772
2. Medications for obesity: A review (2024). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/article-abstract/2821290
3. Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity (2024). Medical Research Archives. Beschikbaar op: https://esmed.org/MRA/mra/article/view/5714
4. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study (2024). Obesity Science & Practice. Beschikbaar op: https://onlinelibrary.wiley.com/doi/abs/10.1002/osp4.762
5. One-year weight reduction with semaglutide or liraglutide in clinical practice (2024). JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2823644
6. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/
7. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Beschikbaar op: https://www.bmj.com/content/384/bmj-2023-076410.long
8. Productkenmerken (2024). Novo Nordisk. Beschikbaar op: https://www.novo-pi.com/ozempic.pdf#guide
9. Wegovy, Werkzame stof: semaglutide (2024). Apotheek.nl. Beschikbaar op: https://www.apotheek.nl/medicijnen/semaglutide?product=ozempic
10. Ozempic (2024). Novo Nordisk. Beschikbaar op: https://www.ozempic.com/
11. Highlights of Prescribing Information (2024). Novo Nordisk. Beschikbaar op: https://www.novo-pi.com/ozempic.pdf
12. Prikinstructies (2024). Novo Nordisk. Beschikbaar op: https://www.novomedlink.com/diabetes/products/treatments/ozempic.html
13. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Beschikbaar op: https://www.e-dmj.org/journal/view.php?number=2843
14. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/
15. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (2024). Obesity Pillars. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/
16. Real-World Effectiveness of Semaglutide and Liraglutide for Weight Management in Overweight or Obese Adults with or Without Type-2 Diabetes Mellitus: Emulation of Randomised Clinical Trials Using UK Electronic Medical Records (2024). The Lancet. Beschikbaar op: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4785364
17. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2024). The American Journal of Cardiology. Beschikbaar op: https://www.ajconline.org/article/S0002-9149(24)00319-9/fulltext
18. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure (2024). Journal of the American College of Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S0735109724081920?via%3Dihub
19. Semaglutide and blood pressure: an individual patient data meta-analysis (2024). European Heart Journal. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11458150/
20. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (2024). JAMA Internal Medicine. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
21. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology (2024). JAMA Internal Medicine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11372653/
22. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024). Diabetes Care. Beschikbaar op: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2
23. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/
24. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes (2024). Journal of Diabetes. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450654/
25. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Beschikbaar op: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7
26. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (2024). Nature Medicine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/
27. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2024). Journal of the American Pharmacists Association. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1544319123003096
28. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Beschikbaar op: https://www.bmj.com/content/384/bmj-2023-076410.long
29. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis (2024). Pharmacology Research. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1043661823003870?via%3Dihub
30. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2) (2024). Journal of Clinical Endocrinology & Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11180500/
31. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial (2024). JMIR Research Protocols. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437224/
32. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease (2024). Kidney International. Beschikbaar op: https://www.kidney-international.org/article/S0085-2538(24)00629-X/fulltext
33. Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective (2024). Journal Brasileiro de Nefrologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11548866/
34. The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review (2024). Pharmacy (Basel). Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10801460/
35. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer (2024). Cancer Metastasis Reviews. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11554930/
36. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/
37. Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations (2024). Cureus. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11456416/
38. The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review (2024). Cureus. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11410460/
39. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024). Journal of the American College of Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S0735109724081166?via%3Dihub
40. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext
41. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2810542
42. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2023). American Pharmacists Association. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1544319123003096
43. Obesity Management in Adults: A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/
44. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/
45. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (2023). Cardiovascular Diabetology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9960425/
46. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF (2023). Journal of the American College of Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S2452302X23002334
47. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/
48. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/
49. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023). Current Obesity Reports. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/
50. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext
51. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis (2023). Endocrine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10902041/
52. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2810542
53. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/
54. Wegovy (semaglutide): a new weight loss drug for chronic weight management (2023). Journal of Investigative Medicine. Beschikbaar op: https://journals.sagepub.com/doi/abs/10.1136/jim-2021-001952
55. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/
56. Once-weekly semaglutide in adolescents with obesity (2022). New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
57. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis (2022). Endocrine. Beschikbaar op: https://link.springer.com/article/10.1007/s12020-021-02945-1
58. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity (2022). JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2796491
59. Once-weekly semaglutide for weight management: a clinical review (2022). Journal of Pharmacy Technology. Beschikbaar op: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272494/
60. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392
61. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC8753508/
62. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review (2022). Clinical Epidemiology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9738168/
63. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review (2022). Therapeutic Advances in Chronic Disease. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260566/
64. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2787907
65. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). JAMA Internal Medicine. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392
66. Clinical review of subcutaneous semaglutide for obesity (2021). Journal of Clinical Pharmacy and Therapeutics. Beschikbaar op: https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.13574
67. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Beschikbaar op: https://link.springer.com/article/10.1007/s12325-021-01710-0
68. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract
69. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
70. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/10.1056/NEJMoa2107519?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
71. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (2021). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2777025
72. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (2020). Clinical Diabetes. Beschikbaar op: https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor
DISCLAIMER
Betrouwbare informatie, verantwoord gedeeld
De inhoud van deze referentielijst is uitsluitend bedoeld voor informatieve doeleinden. De vermelde artikelen en bronnen zijn gebaseerd op openbare wetenschappelijke publicaties en hebben betrekking op het gebruik van Ozempic® en gerelateerde behandelingen. Hoewel we hebben gestreefd naar nauwkeurigheid en volledigheid, raden we aan om professioneel medisch advies in te winnen voordat u beslissingen neemt op basis van de inhoud van deze referenties. BMI Clinic aanvaardt geen aansprakelijkheid voor eventuele onjuistheden of onvolledigheden in de verstrekte informatie.
Voor meer achtergrondinformatie kan je de uitgebreide lijst op de pagina ‘Bronnen‘ raadplegen.